Stockscreener 앱 받기
5.98
0.50%
0.03
시간 외 거래:
5.97
-0.01
-0.17%
전일 마감가:
$5.95
열려 있는:
$6.08
하루 거래량:
78,924
Relative Volume:
1.22
시가총액:
$214.92M
수익:
-
순이익/손실:
-
주가수익비율:
-3.0226
EPS:
-1.9784
순현금흐름:
-
1주 성능:
+0.34%
1개월 성능:
+7.17%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$5.92
$6.08
1주일 범위
$5.89
$6.08
52주 변동 폭
$5.25
$6.10
Anteris Technologies Global Corp Stock (AVR) Company Profile
명칭
Anteris Technologies Global Corp
전화
-
주소
-
AVR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AVR
Anteris Technologies Global Corp
|
5.98 | 214.92M | 0 | 0 | 0 | -1.9784 |
|
ISRG
Intuitive Surgical Inc
|
580.18 | 206.65B | 8.35B | 2.32B | 586.00M | 6.41 |
|
BDX
Becton Dickinson Co
|
248.49 | 68.23B | 20.18B | 1.71B | 3.07B | 5.94 |
|
ALC
Alcon Inc
|
92.32 | 45.66B | 9.76B | 1.16B | 665.00M | 2.34 |
|
RMD
Resmed Inc
|
257.65 | 37.85B | 4.81B | 1.11B | 1.35B | 7.55 |
|
WST
West Pharmaceutical Services Inc
|
343.91 | 24.95B | 2.88B | 499.60M | 321.60M | 6.74 |
Anteris Technologies Global Corp Stock (AVR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-08 | 개시 | Lake Street | Buy |
| 2025-01-07 | 개시 | Barclays | Overweight |
| 2025-01-07 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-01-07 | 개시 | TD Cowen | Buy |
Anteris Technologies Global Corp 주식(AVR)의 최신 뉴스
Head-To-Head Analysis: Anteris Technologies Global (NASDAQ:AVR) vs. Inogen (NASDAQ:INGN) - Defense World
Cantor Fitzgerald Estimates AVR FY2025 Earnings - Defense World
L1 Capital Pty Ltd Acquires Significant Stake in Anteris Technologies Global Corp. - GuruFocus.com
FY2025 Earnings Forecast for AVR Issued By Cantor Fitzgerald - MarketBeat
Anteris Technologies Expands Public Offering with Additional Share Issuance - TipRanks
Anteris Technologies announces partial IPO over-allotment exercise - Investing.com
Anteris Technologies announces partial IPO over-allotment exercise By Investing.com - Investing.com Canada
Healthcare outlook 2025: healthcare and biotech to regain investor focus - Proactive financial news
Anteris Technologies Global Corp’s Quiet Period Set To End on January 22nd (NASDAQ:AVR) - Defense World
Anteris Technologies Announces Partial Over-Allotment Exercise and End of IPO Stabilisation - TipRanks
FY2024 Earnings Forecast for AVR Issued By Cantor Fitzgerald - MarketBeat
Anteris Technologies Global Corp. Rings the Opening Bell - Nasdaq
Anteris Technologies Global (NASDAQ:AVR) Coverage Initiated at Lake Street Capital - Defense World
TD Cowen Begins Coverage on Anteris Technologies Global (NASDAQ:AVR) - Defense World
Barclays Initiates Coverage on Anteris Technologies Global (NASDAQ:AVR) - Defense World
Cantor Fitzgerald Initiates Coverage on Anteris Technologies Global (NASDAQ:AVR) - Defense World
Anteris Technologies Adjusts Stock Positions Between ASX and Nasdaq - TipRanks
Healthcare sector: back in focus in 2025 - Proactive Investors USA
Anteris Technologies Positioned To Capture 4%-5% Of US Transcatheter Valve Replacement Market By 2030: Analyst - Benzinga
Anteris Technologies Global (NASDAQ:AVR) Now Covered by Analysts at TD Cowen - MarketBeat
This Coca-Cola Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Anteris Technologies Global (NASDAQ:AVR) Coverage Initiated by Analysts at Cantor Fitzgerald - MarketBeat
Cantor Fitzgerald starts Anteris stock with Overweight rating - Investing.com
Admedus Limited Announces Approval for First-In-Human Surgical Aortic Valve Replacement Trial of Proprietary ADAPT Single-Piece 3D Aortic Valve At the Leuven University Hospitals - Marketscreener.com
Anteris Technologies’ Bold Shift to U.S. Markets - MSN
Admedus Limited to Relocate Corporate Services Functions to Brisbane; Announces Executive Changes - Marketscreener.com
Heart valve developer Anteris launches IPO - MedTech Dive
Admedus Ltd : Admedus's CardioCel® Cleared for Sale in the US - Marketscreener.com
Anteris Technologies Redeems Convertible Notes - TipRanks
Anteris Technologies Announces New Director Appointment - TipRanks
Anteris Technologies Debuts on NASDAQ with IPO - MSN
Anteris Technologies Prepares for Stock Market Expansion - MSN
Anteris Completes Key Animal Study for EFS Submission - Marketscreener.com
Allied Healthcare Group Ltd : Allied reports no calcification from phase II CardioCel patients after 5 years - Marketscreener.com
Anteris Technologies Ltd Provides Data Update on First in Human Study of DurAVR THV Presented At New York Valves 2024 - Marketscreener.com
Anteris Technologies Announces Presentation of First-In-Human Data for its Novel TAVR Product, DurAVR™ at the 2022 Annual TCT Congress in Boston - Marketscreener.com
Admedus Limited Appoints Maja Mcguire as Company Secretary - Marketscreener.com
Anteris Submits Confidential Draft Registration Statement for Proposed US IPO - Marketscreener.com
Anteris Technologies Ltd Reports Successful Interim Results for the First-In-Human Trial - Marketscreener.com
US FDA Allows Manufacturing to Start at Anteris Technologies' Expanded Production Facility for DurAVR THV - Marketscreener.com
Anteris Technologies Ltd Announces FDA Allows Manufacturing to Begin At Expanded Facility - Marketscreener.com
Admedus Limited Announces Management Changes - Marketscreener.com
Anteris Technologies Global Corp. Announces Launch of U.S. Initial Public Offering - Marketscreener.com
Anteris Technologies and v2vmedtech Announce Concept Lock of Next Generation Mitral and Tricuspid Repair System as VClip Passes Animal Study - Marketscreener.com
Anteris Technologies CEO talks A$35 million raise and 2023 milestones - Marketscreener.com
Anteris Technologies closes USD 88.8M US IPO - Medical Buyer
Anteris re-domiciliation finalised: shares trading on ASX and Nasdaq - Proactive financial news
Anteris Technologies Completes $89 Million US IPO; to list CDIs on ASX; Shares Fall 15% - Marketscreener.com
Anteris Technologies Advances with SEC Filing - TipRanks
Anteris Technologies Completes $88.8M NASDAQ IPO for Revolutionary Heart Valve Development - StockTitan
Anteris Technologies Global Corp. Announces Closing of $88.8 Million U.S. Initial Public Offering - Business Wire
Anteris Technologies Global Corp (AVR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.40%
자본화:
|
볼륨(24시간):